Dr. Frank A. Vicini

Claim this profile

GenesisCare USA - Troy

Studies Lung Cancer
Studies Cancer
22 reported clinical trials
60 drugs studied

Area of expertise

1Lung Cancer
Frank A. Vicini has run 7 trials for Lung Cancer. Some of their research focus areas include:
Stage III
Stage IV
Stage II
2Cancer
Frank A. Vicini has run 7 trials for Cancer. Some of their research focus areas include:
Stage III
Stage IV
p16 positive

Affiliated Hospitals

Image of trial facility.
GenesisCare USA - Troy
Image of trial facility.
GenesisCare USA - Farmington Hills

Clinical Trials Frank A. Vicini is currently running

Image of trial facility.

Monalizumab or Oleclumab with Durvalumab and Radiation

for Lung Cancer

This phase I trial studies the safety of adding durvalumab to accelerated hypofractionated radiation therapy (ACRT) or conventionally fractionated radiation therapy, as well as the safety of adding either monalizumab or oleclumab to durvalumab plus conventionally fractionated radiation therapy in treating patients with non-small cell lung cancer that has spread to nearby tissue or lymph nodes (locally advanced). Accelerated hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Immunotherapy with monoclonal antibodies, such as durvalumab and monalizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Oleclumab is in a class of medications called monoclonal antibodies. It binds to a protein called CD73, which is found on some types of tumor cells. Oleclumab may block CD73 and help the immune system kill tumor cells. It is not yet known whether adding durvalumab to ACRT or adding monalizumab or oleclumab to durvalumab plus conventionally fractionated radiation therapy will work better in treating patients with non-small cell lung cancer.
Recruiting1 award Phase 110 criteria
Image of trial facility.

High-Dose vs Low-Dose Cisplatin with Radiation

for Head and Neck Cancer

This phase II/III trial compares the effect of the combination of high-dose cisplatin every three weeks and radiation therapy versus low-dose cisplatin weekly and radiation therapy for the treatment of patients with locoregionally advanced head and neck cancer. Chemotherapy drugs, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. This study is being done to find out if low-dose cisplatin given weekly together with radiation therapy is the same or better than high-dose cisplatin given every 3 weeks together with radiation therapy in treating patients with head and neck cancer.
Recruiting1 award Phase 2 & 335 criteria

More about Frank A. Vicini

Clinical Trial Related4 years of experience running clinical trials · Led 22 trials as a Principal Investigator · 8 Active Clinical Trials
Treatments Frank A. Vicini has experience with
  • Radiation Therapy
  • Atezolizumab
  • Flutamide
  • Bicalutamide
  • Triptorelin
  • Degarelix

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Frank A. Vicini specialize in?
Frank A. Vicini focuses on Lung Cancer and Cancer. In particular, much of their work with Lung Cancer has involved Stage III patients, or patients who are Stage IV.
Is Frank A. Vicini currently recruiting for clinical trials?
Yes, Frank A. Vicini is currently recruiting for 8 clinical trials in Troy Michigan. If you're interested in participating, you should apply.
Are there any treatments that Frank A. Vicini has studied deeply?
Yes, Frank A. Vicini has studied treatments such as Radiation Therapy, Atezolizumab, Flutamide.
What is the best way to schedule an appointment with Frank A. Vicini?
Apply for one of the trials that Frank A. Vicini is conducting.
What is the office address of Frank A. Vicini?
The office of Frank A. Vicini is located at: GenesisCare USA - Troy, Troy, Michigan 48098 United States. This is the address for their practice at the GenesisCare USA - Troy.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.